secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001628280-24-003506
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo: ST-920 gene therapy shows sustained efficacy; defers Phase 3 pending partnership
--------------------------------------------------------------------------------

- As of Sep 19, 2023 cutoff, 24 patients dosed; all 12 withdrawn from ERT remain off ERT with sustained supraphysiological α-Gal A activity.
- In dose escalation phase, all 9 patients had sustained elevated α-Gal A activity for nearly 3 years; 5 ERT patients completed withdrawal.
- At highest dose (2.63×10^13 vg/kg), ERT-naïve patients showed supraphysiological α-Gal A up to ~500 days with lyso-Gb3 reduction/stabilization.
- Mean annualized eGFR slope -0.915 mL/min/1.73m²/yr; 69% improved total FOS-MSSI; statistically significant SF-36 and GSRS improvements.
- Company defers further investment in registrational trial planning until collaboration partnership or financing is secured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024003506/0001628280-24-003506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024003506/sgmo-20240205.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-003506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer